Table 3.

Predictors of cancer-specific mortality in patients with bone metastatic prostate cancer.

	Univariate			Multivariatea
	HR	(95% CI)	P	HR	(95% CI)	P
Age (y)	1.009	(0.985–1.034)	0.447
BMI	1.044	(0.961–1.135)	0.315
Gleason score (≥8)	2.663	(1.421–4.994)	0.002
T stage (≥T3)	1.529	(0.705–3.318)	0.282
PSA	1.001	(0.999–1.002)	0.295
Time to PSA nadir	0.879	(0.808–0.956)	0.003
PSA nadir	1.001	(1.001–1.002)	0.002	1.006	(0.001–1.011)	0.012
PSA nadir maintenance period	0.924	(0.868–0.962)	0.003
PSA velocity	1.000	(1.000–1.000)	0.149
ALP	2.121	(1.353–3.324)	0.001	1.002	(1.001–1.003)	0.016
VAS pain score (≥1)	2.079	(1.309–3.301)	0.002
ECOG PS (≥1)	2.238	(1.385–3.616)	0.001	2.685	(1.287–5.605)	0.009
Progression to CRPC	2.255	(1.442–3.526)	<0.001
Number of bone lesions	1.017	(0.997–1.037)	0.102

ALP, alkaline phosphatase; BMI, body mass index; CCI, Charlson Comorbidity Index; CI, confidence interval; CRPC, Castrate-resistance prostate cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; HR, hazards ratio; LN, lymph node; PSA, prostate-specific antigen; VAS, Visual Analogue Scale.

^aForward step-wise conditional method.